Eylea Solution for Injection
Aflibercept
114.3 mg/ml
CATALENT PHARMA SOLUTIONS
| Pack size | 1 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 3028.60 AED |
Indications
Eylea Solution for Injection is used for:
The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Aflibercept :
Mechanism of Action
Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
Note
Eylea 114.3 mg/ml Solution for Injection manufactured by CATALENT PHARMA SOLUTIONS. Its generic name is Aflibercept. Eylea is availble in Saudi Arabia.
Farmaco SA drug index information on Eylea Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.